Summary
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?
The mean of analysts' price targets for Pharvaris (PHVS) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pharvaris N.V. (NASDAQ:PHVS) Receives $41.70 Consensus Target Price from Brokerages
Shares of Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to
Pharvaris N.V. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Andreas Halvorsen Viking Global Investors LP | 3.65M | $88.97M | $110.11M | $21.14M | 23.76% |
 John H. Burbank III Passport Capital LLC | 375,000 | $9.36M | $11.3M | $1.95M | 20.8% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.01M | $26.29M | $30.35M | $4.06M | 15.45% |
| CB Curtis Burkholder Bare Financial Services, Inc | 6 | $170 | $180.84 | $10.84 | 6.38% |
| MS Mark Schafer Police & Firemen's Retirement System of New Jersey | 8,239 | $199,570.67 | $248,323.46 | $48,752.79 | 24.43% |
Pharvaris N.V. (PHVS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharvaris N.V. ever had a stock split?
Pharvaris N.V. Profile
| Biotechnology Industry | Healthcare Sector | Berndt Axel Edvard Modig CEO | NASDAQ (NGS) Exchange | N69605108 CUSIP |
| NL Country | 108 Employees | - Last Dividend | - Last Split | 5 Feb 2021 IPO Date |
Overview
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates on a global scale with operational footprints in the Netherlands, Switzerland, and the United States. The company's research and development efforts are primarily focused on addressing the unmet medical needs of patients suffering from hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition. By leveraging cutting-edge scientific research and drug development processes, Pharvaris aims to bring novel treatments to market, significantly improving patient outcomes and quality of life.
Products and Services
- PHA121
PHA121 is a small molecule bradykinin B2-receptor antagonist currently in Phase II clinical trials. This promising therapeutic candidate is designed to treat hereditary angioedema (HAE) by targeting and inhibiting the pathway believed to contribute to HAE symptoms, such as swelling and pain. By focusing on this specific pathway, PHA121 aims to offer a new and effective treatment option for managing this rare condition.
- PHVS416
PHVS416 is an on-demand treatment developed for the rapid relief of acute hereditary angioedema (HAE) attacks. This soft capsule formulation is designed to ensure rapid exposure of the active drug, aiming to reduce the severity and duration of HAE episodes. Currently under Phase 2 clinical trial, PHVS416 represents Pharvaris's commitment to providing timely and effective solutions for HAE sufferers during acute attack phases.
- PHVS719
PHVS719 is a prophylactic (preventive) treatment option that Pharvaris is developing for patients with hereditary angioedema (HAE). Formulated as an extended-release tablet, this investigational product is intended to provide long-lasting protection against HAE attacks. Positioned in Phase 1 clinical trials, PHVS719 exemplifies the company’s strategy of addressing both acute treatment needs and ongoing management of HAE, enhancing the overall quality of care for patients living with this chronic condition.
